What is COVID-19?

COVID-19 is a disease caused by the virus called severe acute respiratory syndrome 2 coronavirus (SARS-CoV-2). SARS-CoV-2 is a new strain of coronavirus that was not detected in humans until December 2019. The current COVID-19 outbreak broke out in late 2019 and was declared a pandemic by the World Health Organization (WHO) on March 11, 2020. It is the first pandemic caused by a coronavirus. There are many different types of coronaviruses. Although they mainly affect animals, some can infect humans.

Medicines and vaccines used to treat COVID-19 (SARS-CoV-2)

Below is a list of medicines authorized in the European Union (EU) to treat or prevent COVID-19, following a scientific evaluation by the European Medicines Agency (EMA). It provides details of other potential treatments and vaccines that the EMA is evaluating or supporting during research and development.

Vaccine leaflets COVID-19 (SARS-CoV-2)

Coronavirus vaccine Janssen

Chemical substance

COVID-19 vaccine (Ad26.COV2-S [recombinant])

ATC code

J07BX03 • Antiinfectives for systemic use | Viral vaccines | Other viral vaccines

Leaflet published : 11/03/2021
Leaflet updated : 26/03/2024

Coronavirus vaccine Vaxzevria (AstraZeneca)

Chemical substance

COVID-19 vaccine (ChAdOx1-S [recombinant])

ATC code

J07BX03 • Antiinfectives for systemic use | Viral vaccines | Other viral vaccines

Leaflet published : 18/02/2021
Leaflet updated : 13/03/2024

Coronavirus vaccine Spikevax (Moderna Biotech)

Chemical substance

COVID-19 mRNA vaccine (with modified nucleosides)

ATC code

J07BX03 • Antiinfectives for systemic use | Viral vaccines | Other viral vaccines

Leaflet published : 20/01/2021
Leaflet updated : 01/02/2024

Coronavirus vaccine Comirnaty adults (Pfizer / BioNTech)

Chemical substance

COVID-19 mRNA vaccine (with modified nucleosides)

ATC code

J07BX03 • Antiinfectives for systemic use | Viral vaccines | Other viral vaccines

Leaflet published : 12/01/2021
Leaflet updated : 15/12/2023

Coronavirus vaccine Comirnaty children (Pfizer / BioNTech)

Chemical substance

COVID-19 mRNA vaccine (with modified nucleosides)

ATC code

J07BX03 • Antiinfectives for systemic use | Viral vaccines | Other viral vaccines

Leaflet published : 12/01/2021
Leaflet updated : 15/12/2023

Coronavirus vaccine Nuvaxovid (Novavax)

Chemical substance

COVID-19 vaccine (recombinant, with adjuvant)

ATC code

J07BX03 • Antiinfectives for systemic use | Viral vaccines | Other viral vaccines

Leaflet published : 20/12/2021
Leaflet updated : 08/11/2023

EMA authorized treatments in the EU for COVID-19 (SARS-CoV-2)

PAXLOVID 150mg+100mg

Chemical substance

PF-07321332 + ritonavir

Leaflet published : 28/01/2022
Leaflet updated : 14/03/2024

Kineret 150mg/ml

Chemical substance

Anakinra

ATC code

L04AC03 • Antineoplastic and immunomodulating agents | Immunosuppressants | Interleukin inhibitors

Leaflet published : 04/08/2009
Leaflet updated : 21/03/2024

Regkirona 60mg/ml

Chemical substance

Regdanvimab

ATC code

J06BD06 • Antiinfectives for systemic use | Immunoglobulins | Antiviral monoclonal antibodies

Leaflet published : 12/11/2021
Leaflet updated : 25/08/2023

RoActemra 80mg

Chemical substance

Tocilizumab

ATC code

L04AC07 • Antineoplastic and immunomodulating agents | Immunosuppressants | Interleukin inhibitors

Leaflet published : 08/01/2010
Leaflet updated : 20/03/2024

RoActemra 162mg

Chemical substance

Tocilizumab

ATC code

L04AC07 • Antineoplastic and immunomodulating agents | Immunosuppressants | Interleukin inhibitors

Leaflet published : 08/01/2010
Leaflet updated : 20/03/2024

RoActemra 200mg

Chemical substance

Tocilizumab

ATC code

L04AC07 • Antineoplastic and immunomodulating agents | Immunosuppressants | Interleukin inhibitors

Leaflet published : 08/01/2010
Leaflet updated : 20/03/2024

RoActemra 400mg

Chemical substance

Tocilizumab

ATC code

L04AC07 • Antineoplastic and immunomodulating agents | Immunosuppressants | Interleukin inhibitors

Leaflet published : 08/01/2010
Leaflet updated : 20/03/2024

Ronapreve 120mg/ml+120mg/ml

Chemical substance

Casirivimab + imdevimab

ATC code

J06BD07 • Antiinfectives for systemic use | Immunoglobulins | Antiviral monoclonal antibodies

Leaflet published : 12/11/2021
Leaflet updated : 01/02/2024

Ronapreve 300mg+300mg

Chemical substance

Casirivimab + imdevimab

ATC code

J06BD07 • Antiinfectives for systemic use | Immunoglobulins | Antiviral monoclonal antibodies

Leaflet published : 12/11/2021
Leaflet updated : 01/02/2024

Veklury 100mg

Chemical substance

Remdesivir

ATC code

J05AB16 • Antiinfectives for systemic use | Direct acting antivirals | Nucleosides and nucleotides excl. reverse transcriptase inhibitors

Leaflet published : 18/07/2020
Leaflet updated : 05/12/2023

Xevudy 500mg

Chemical substance

Sotrovimab

ATC code

J06BD05 • Antiinfectives for systemic use | Immunoglobulins | Antiviral monoclonal antibodies

Leaflet published : 16/12/2021
Leaflet updated : 19/03/2024

Treatments with Marketing authorisation application submitted to EMA for COVID-19 (SARS-CoV-2)

Lagevrio 200mg

Chemical substance

Molnupiravir

ATC code

J05AB18 • Antiinfectives for systemic use | Direct acting antivirals | Nucleosides and nucleotides excl. reverse transcriptase inhibitors

Leaflet published : 04/11/2011

Olumiant 2mg

Chemical substance

Baricitinib

ATC code

L04AA37 • Antiinfectives for systemic use | Direct acting antivirals | Nucleosides and nucleotides excl. reverse transcriptase inhibitors

Leaflet published : 16/03/2017
Leaflet updated : 30/10/2023

Olumiant 4mg

Chemical substance

Baricitinib

ATC code

L04AA37 • Antiinfectives for systemic use | Direct acting antivirals | Nucleosides and nucleotides excl. reverse transcriptase inhibitors

Leaflet published : 16/03/2017
Leaflet updated : 30/10/2023